Navigation Links
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Date:2/27/2008

- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus

- Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of

mTOR - Results of RECORD-1 trial address unmet medical need in renal cell cancer

with worldwide regulatory filings planned for second half of 2008

- Complete results to be submitted as late-breaking abstract for

presentation at the American Society of Clinical Oncology meeting

EAST HANOVER, N.J., Feb. 28 /PRNewswire-FirstCall/ -- An independent data monitoring committee stopped a major Phase III clinical trial of the investigational drug everolimus (RAD001) today after interim results showed significantly better progression-free survival in patients with advanced kidney cancer who received everolimus compared to placebo.

The committee stopped the trial of more than 400 patients conducted in 12 countries because the study met its primary endpoint. The interim findings are being shared with investigators to allow them to offer everolimus to patients remaining on placebo. Everolimus may fulfill an unmet medical need for patients with advanced renal cell cancer (RCC) who currently have no approved treatment options.

Everolimus is a once-daily oral therapy that offers a new approach to cancer treatment by inhibiting the mTOR protein, a central regulator of tumor cell division and blood vessel growth in cancer cells. The trial included patients who had their cancer worsen despite receiving approved treatments for RCC, such as Nexavar(R) (sorafenib)(1) or Sutent(R) (sunitinib)(2) or both. In addition, prior therapy with Avastin(R) (bevacizumab)(3) and interferon was allowed.

"Everolimus has the potential to greatly help patients with kidney cancer, especially in advanced stage who up to now
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
5. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
6. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
7. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 11, 2011 MonoSol Rx, a specialty pharmaceutical ... platform, in collaboration with APR Applied Pharma Research ... FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is ... Company made the strategic decision to reacquire the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Product Profiles: Systemic ... and hope to market ... order this report: ...
Cached Medicine Technology:MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 2MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 3
(Date:1/22/2015)... Bradley, Illinois (PRWEB) January 22, 2015 Deer ... -- will host a Valentine’s Day Happy Hour from 3 p.m. ... located at 12500 Regency Parkway in Huntley, Illinois, serves adults with ... Happy Hour event will include Valentine's Day treats, games and sweetheart-themed ...
(Date:1/22/2015)... Va. (PRWEB) January 22, 2015 Liberty University ... Counseling (M.A.) program from the Council for Accreditation ... program, part of Liberty’s Center for Counseling & Family ... founding dean of the university’s new School of Behavioral Sciences. ...
(Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... Group, Inc. will provide substantial ... revenues for the company, ... American Health Resorts, Inc. (Pink Sheets:,CAHR) of Beverly Hills, California, today ... corporate note deal valued at,approximately $8 million., With Momentum Medical ...
... ... Total Debt Reduced, BIRMINGHAM, Ala., Feb. 25 HealthSouth,Corporation (NYSE: ... the fourth quarter ended December 31, 2007. Compared to the,fourth quarter ... by 4.6% and discharges increased by,0.9%., "We are pleased with ...
... 25 Lung Cancer Alliance,(LCA) cautioned today that recently ... more people each year than all the other,major cancers ... of government statistics,entitled Cancer Facts and Figures for 2008, ... been made against cancer over the,past 15 years.", ...
... ... - ANNUAL REVENUES INCREASED 34.5% ... FFO PER SHARE UP 7.8%, NEWPORT BEACH, Calif., Feb. 25 Nationwide,Health Properties, Inc. ... investment activity., "We ended 2007 on a strong note with fourth quarter revenues up ...
... COLUMBUS, Ohio Scientists have identified the role of ... in resisting certain classes of antibiotics. , The finding ... could target bacterial resistance at its cellular source. Before ... of the activities at play in the conflict between ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) ... on March 3, 2008. Management will not be ... and explanations of,variances will be included in the ... be released before markets open., About Sunrise ...
Cached Medicine News:Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 2Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 3Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 4Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 2Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 3Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 4Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 5Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 6Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 7Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 8Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 9Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 10Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 11Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 12Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 13Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 14Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 15Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 16Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 17Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 18Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 19Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 20Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 21Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 22Health News:'Enormous Progress' in Reducing Cancer Does Not Include Lung Cancer 2Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 2Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 3Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 4Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 5Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 6Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 7Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 8Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 9Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 10Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 11
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... the Finntip Wide is designed especially for ... genomic DNA. This tip eliminates the mechanical ... excellent for use with extremely viscous liquids. ... of the orifice is 1.1 mm or ...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels...
Medicine Products: